65 related articles for article (PubMed ID: 19154236)
1. Wild type and melanoma-associated mutant p16(IN4a) proteins do not oligomerize in vivo.
McKenzie H; Becker TM; Scurr LL; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2009 Feb; 22(1):131-3. PubMed ID: 19154236
[No Abstract] [Full Text] [Related]
2. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
Becker TM; Rizos H; Kefford RF; Mann GJ
Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
[TBL] [Abstract][Full Text] [Related]
3. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
4. The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells.
Dirks PB; Rutka JT; Hubbard SL; Mondal S; Hamel PA
Oncogene; 1998 Aug; 17(7):867-76. PubMed ID: 9780003
[TBL] [Abstract][Full Text] [Related]
5. [Expression and regulation of p16 in osteosarcoma].
Shi X; Ma Z; Wang D; Liang Y; Li H; Wang J
Zhonghua Wai Ke Za Zhi; 1999 Dec; 37(12):733-6. PubMed ID: 11829939
[TBL] [Abstract][Full Text] [Related]
6. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Nielsen GP; Burns KL; Rosenberg AE; Louis DN
Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
[TBL] [Abstract][Full Text] [Related]
7. A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6.
Jones R; Ruas M; Gregory F; Moulin S; Delia D; Manoukian S; Rowe J; Brookes S; Peters G
Cancer Res; 2007 Oct; 67(19):9134-41. PubMed ID: 17909018
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
[TBL] [Abstract][Full Text] [Related]
9. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins.
Zacharek SJ; Xiong Y; Shumway SD
Cancer Res; 2005 Dec; 65(24):11354-60. PubMed ID: 16357142
[TBL] [Abstract][Full Text] [Related]
10. Over-expression of CDKIs p15INK4b, p16INK4a and p21CIP1/WAF1 genes mediate growth arrest in human osteosarcoma cell lines.
Agiostratidou G; Derventzi A; Gonos ES
In Vivo; 2001; 15(5):443-6. PubMed ID: 11695244
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo tumor growth inhibition by a p16-mimicking peptide in p16INK4A-defective, pRb-positive human melanoma cells.
Noonan DM; Severino A; Morini M; Tritarelli A; Manente L; D'Agnano I; Starace G; Baldi A; Lombardi D; Albini A; Felsani A; Paggi MG
J Cell Physiol; 2005 Mar; 202(3):922-8. PubMed ID: 15389561
[TBL] [Abstract][Full Text] [Related]
12. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
13. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
[TBL] [Abstract][Full Text] [Related]
14. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
Ceha HM; Nasser I; Medema RH; Slebos RJ
Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
[TBL] [Abstract][Full Text] [Related]
15. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells.
Craig C; Kim M; Ohri E; Wersto R; Katayose D; Li Z; Choi YH; Mudahar B; Srivastava S; Seth P; Cowan K
Oncogene; 1998 Jan; 16(2):265-72. PubMed ID: 9464545
[TBL] [Abstract][Full Text] [Related]
16. Expression of p16INK4A variants in senescent human fibroblasts independent of protein phosphorylation.
Weebadda WK; Jackson TJ; Lin AW
J Cell Biochem; 2005 Apr; 94(6):1135-47. PubMed ID: 15668906
[TBL] [Abstract][Full Text] [Related]
17. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
18. Expression of HERV-K correlates with status of MEK-ERK and p16INK4A-CDK4 pathways in melanoma cells.
Li Z; Sheng T; Wan X; Liu T; Wu H; Dong J
Cancer Invest; 2010 Dec; 28(10):1031-7. PubMed ID: 20874005
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis.
Zhao Y; Zhang Y; Yang Z; Li A; Dong J
Biochem Biophys Res Commun; 2008 Jun; 370(3):509-13. PubMed ID: 18402768
[TBL] [Abstract][Full Text] [Related]
20. Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations.
Becker TM; Rizos H; de la Pena A; Leclercq IA; Woodruff S; Kefford RF; Mann GJ
Biochem Biophys Res Commun; 2005 Jul; 332(3):873-9. PubMed ID: 15913553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
